Relevant bibliographies by topics / Benzodiazepine

Academic literature on the topic 'Benzodiazepine'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Benzodiazepine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Benzodiazepine"

1

Nsira, Asma, Ahlem Karoui, Rafik Gharbi, and Moncef Msaddek. "Chemoselectivity of the 1,3-Dipolar Cycloaddition of Some Diazoalkanes with 1,5-Benzodiazepine Derivatives." Journal of Chemical Research 36, no. 3 (March 2012): 152–56. http://dx.doi.org/10.3184/174751912x13300109535030.

Full text
Abstract:
Benzodiazepines are pharmaceutically important synthetic materials. Reaction of the 4-(2-hydroxyphenyl)-1,5-benzodiazepin-2-one with 2-diazopropane (DAP) gave a mixture of the 2-isopropylether of 4-(2-hydroxyphenyl)-3H-1,5-benzodiazepine and 1-isopropyl-4-(2-hydroxyphenyl)-3H-1,5-benzodiazepin-2-one. Whilst diphenyldiazomethane (DPDM) gave 1-benzhydryl-4-(2-hydroxyphenyl)-3H-1,5-benzodiazepin-2-one. Reaction of the corresponding thione with DAP led to the 2-isopropylthioether of 4-(2-hydroxyphenyl)-3H-1,5-benzodiazepine and 1-isopropyl-4-(2-hydroxyphenyl)-1,5-benzodiazepine-2-thione while the reaction with DPDM gave the 2-benzhydrylthioether of 4-(2-hydroxyphenyl)-3H-1,5-benzodiazepine. The characterisation of these prepared - N, - O and - S alkylated benzodiazepines involved 1D and 2D-NMR techniques, mass spectrometry and elemental analysis.
APA, Harvard, Vancouver, ISO, and other styles
2

Rotaru, Luciana Teodora, Paul Nedelea, Renata-Maria Varut, Alina Petrica, Silvia Nica, Catalin Bouros, Diana Cimpoesu, Mihaela Corlade, Mihai Banicioiu Covei, and Marius Novac. "Determining the Influence of Alcohol on the Pharmacological Effect of Benzodiazepines by Molecular Docking Tehnique." Revista de Chimie 70, no. 3 (April 15, 2019): 814–19. http://dx.doi.org/10.37358/rc.19.3.7013.

Full text
Abstract:
Benzodiazepines represents a large category of medications that were originally developed to treat anxiety disorders or issues with anxiety, seizures, and issues with sleeping. The most common drugs abused along with benzodiazepines are other benzodiazepines, prescription pain medications and alcohol. Alcohol and benzodiazepine have a synergistic depressant effect on the central nervous system. Combining alcohol with benzodiazepines can be dangerous practice even if it is engaged in only occasionally. In the present study, using molecular docking technique we followed the binding energy of benzodiazepines with benzodiazepine receptor and efficacy of the flumazenil antidote against benzodiazepine in the presence and absence of alcohol. We realized correlation study of molecular descriptors value of benzodiazepines with benzodiazepine-GABAA complex binding energy.
APA, Harvard, Vancouver, ISO, and other styles
3

Lyukshenko, Natalya I., Roman G. Nikitin, and Yury V. Morozhenko. "New technology to obtain 1-methyl-5-pnenyl-7-chloro- 1,3-dihydro-2H-[1,4]-benzodiazepine-2-one." Butlerov Communications 60, no. 10 (October 31, 2019): 24–31. http://dx.doi.org/10.37952/roi-jbc-01/19-60-10-24.

Full text
Abstract:
At present, benzodiazepine derivatives being used widely, they continue to occupy a leading position among the drugs of the anxiolytic group. Most anxiolytics of the benzodiazepine structure are derivatives of 1,4-benzodiazepine. The basis of the chemical benzodiazepine structure consists of a benzene ring connected to a seven-membered heterocyclic ring containing two nitrogen atoms (diazepine) at positions 1 and 4. All the benzodiazepine derivatives used in the clinic also have a second benzene ring attached to carbon. The presence of a halogen or a nitro group is essential to display its activity. Diazepam (1-methyl-5-phenyl-7-chloro-1,3-dihydro-2H- [1,4] benzodiazepin-2-one) is in the list of necessary and important medicinal products. The urgent issue is the development of a new method to synthesize 1-methyl-5-phenyl-7-chloro-1,3-dihydro-2H-[1,4]-benzodiazepines-2-one that would allow producing the drug in the required quantities and for mass consumption. The search for possible effective ways of synthesizing 1-methyl-5-phenyl-7-chlorine-1,3-dihydro-2H-[1,4]-benzodiazepines-2-one for manufacturing application is of great scientific and practical interest. The purpose of our work is to search for a rational method to synthesize the target product, experimental study of the chemical processes to develop the most optimal methods to produce the product. The technology to produce 1-methyl-5-phenyl-7-chlor-1,3-dihydro-2H-[1,4]-benzodiazepine-2-one on an industrial scale was developed. The synthesis of 2-benzoyl-2',4-dichloro-N-methylacetanilide by condensation of 2-methylamine-5-chlorobenzophenone with chloracetyl chloride in carbon tetrachloride without further treatment of the reaction mass with water and sodium carbonate was developed. The highest yield of 1-methyl-5-phenyl-7-chlorine-1,3-dihydro-2H-[1,4]-benzodiazepines-2-one was shown to be obtained if the cyclization reaction is carried out in isopropyl alcohol. The reaction mixture composition in interaction of 2-benzoyl- 2',4 -dichloro-N-methylacetanilide with urotropin plays the defining role in the formation of the target product.
APA, Harvard, Vancouver, ISO, and other styles
4

Muzaale, Abimereki D., Matthew Daubresse, Sunjae Bae, Nadia M. Chu, Krista L. Lentine, Dorry L. Segev, and Mara McAdams-DeMarco. "Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis." Clinical Journal of the American Society of Nephrology 15, no. 6 (May 26, 2020): 794–804. http://dx.doi.org/10.2215/cjn.13341019.

Full text
Abstract:
Background and objectivesMortality from benzodiazepine/opioid interactions is a growing concern in light of the opioid epidemic. Patients on hemodialysis suffer from a high burden of physical/psychiatric conditions, which are treated with benzodiazepines, and they are three times more likely to be prescribed opioids than the general population. Therefore, we studied mortality risk associated with short- and long-acting benzodiazepines and their interaction with opioids among adults initiating hemodialysis.Design, setting, participants, & measurementsThe cohort of 69,368 adults initiating hemodialysis (January 2013 to December 2014) was assembled by linking US Renal Data System records to Medicare claims. Medicare claims were used to identify dispensed benzodiazepines and opioids. Using adjusted Cox proportional hazards models, we estimated the mortality risk associated with benzodiazepines (time varying) and tested whether the benzodiazepine-related mortality risk differed by opioid codispensing.ResultsWithin 1 year of hemodialysis initiation, 10,854 (16%) patients were dispensed a short-acting benzodiazepine, and 3262 (5%) patients were dispensed a long-acting benzodiazepine. Among those who were dispensed a benzodiazepine during follow-up, codispensing of opioids and short-acting benzodiazepines occurred among 3819 (26%) patients, and codispensing of opioids and long-acting benzodiazepines occurred among 1238 (8%) patients. Patients with an opioid prescription were more likely to be subsequently dispensed a short-acting benzodiazepine (adjusted hazard ratio, 1.66; 95% confidence interval, 1.59 to 1.74) or a long-acting benzodiazepine (adjusted hazard ratio, 1.11; 95% confidence interval, 1.03 to 1.20). Patients dispensed a short-acting benzodiazepine were at a 1.45-fold (95% confidence interval, 1.35 to 1.56) higher mortality risk compared with those without a short-acting benzodiazepine; among those with opioid codispensing, this risk was 1.90-fold (95% confidence interval, 1.65 to 2.18; Pinteraction<0.001). In contrast, long-acting benzodiazepine dispensing was inversely associated with mortality (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72 to 0.99) compared with no dispensing of long-acting benzodiazepine; there was no differential risk by opioid dispensing (Pinteraction=0.72).ConclusionsCodispensing of opioids and short-acting benzodiazepines is common among patients on dialysis, and it is associated with higher risk of death.
APA, Harvard, Vancouver, ISO, and other styles
5

Williams, Hugh, Doug Handyside, Kirsty Bashford, and Adenekan Oyefeso. "Service response to benzodiazepine use in opiate addicts: a national postal survey." Irish Journal of Psychological Medicine 22, no. 1 (March 2005): 15–18. http://dx.doi.org/10.1017/s0790966700008739.

Full text
Abstract:
AbstractObjectives: The study reports on benzodiazepine use among opiate dependent patients attending National Health Service community prescribing services and examines current practice in the clinical management of benzodiazepine dependence.Method: A postal questionnaire survey of 174 NHS substance misuse services in England and Wales.Results: A 71% response rate was achieved. Services estimated the prevalence of benzodiazepine use to be 40% and the prevalence of benzodiazepine dependence to be less than 25% among opiate dependent patients in treatment. Illicit supplies (street) and general practitioners were regarded as the most common source of benzodiazepines. The most commonly reported reasons for benzodiazepine use were for the direct intoxicating effects and for the treatment of anxiety/insomnia. The majority of services (93,75%) reported prescribing benzodiazepines to patients for benzodiazepine detoxification while 43 (35%) reported prescribing for benzodiazepine maintenance treatment. The variations in benzodiazepine prescribing practices across services are described.Conclusions: Benzodiazepine use remains common among opiate addicts in contact with treatment services. The majority of services surveyed reported prescribing benzodiazepines but there was much variation in clinical practice nationally. There is need for further research to identify effective treatment approaches for comorbid benzodiazepine dependence in opiate misusers.
APA, Harvard, Vancouver, ISO, and other styles
6

van der Sluiszen, Nick, Annemiek Vermeeren, Stefan Jongen, Frederick Vinckenbosch, and Johannes Ramaekers. "Influence of Long-Term Benzodiazepine use on Neurocognitive Skills Related to Driving Performance in Patient Populations: A Review." Pharmacopsychiatry 50, no. 05 (July 4, 2017): 189–96. http://dx.doi.org/10.1055/s-0043-112755.

Full text
Abstract:
AbstractAcute benzodiazepine intoxication produces severe impairment of neurocognitive skills related to driving. It is less clear whether such impairments also occur in patients who use benzodiazepines chronically. The current review evaluated neurocognitive skills of long-term benzodiazepine users and addressed 2 major questions: do long-term users develop tolerance for the impairing effects of benzodiazepines on neurocognitive performance, and if so, does tolerance warrant a change in driver fitness classification systems that currently deem users of benzodiazepines unfit to drive? Neurocognitive impairments were reported in patients who on average used benzodiazepines for 5–15 years. In addition, sensitivity to acute benzodiazepine impairment decreased in long-term users, suggesting (partial) tolerance. Definitions of clinical relevance of neurocognitive impairments in long-term users and how these were affected by duration of benzodiazepine use were generally lacking. Also, sensitivity of neurocognitive tasks to drug effects and their validity to predict fitness to drive were generally unknown. Because of these limitations, no firm conclusion can be drawn regarding a re-classification of long-term benzodiazepine effects on driver fitness.
APA, Harvard, Vancouver, ISO, and other styles
7

Grønbæk, Lisbet, Hugh Watson, Hendrik Vilstrup, and Peter Jepsen. "Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites." United European Gastroenterology Journal 6, no. 3 (August 23, 2017): 407–12. http://dx.doi.org/10.1177/2050640617727179.

Full text
Abstract:
Background There is limited evidence to support the belief that benzodiazepines increase cirrhosis patients’ risk of hepatic encephalopathy (HE). Objective We aimed to examine the association between benzodiazepine use and HE development in cirrhosis patients. Methods We used data on 865 cirrhosis patients with ascites from three trials to study the effect of benzodiazepine use on development of first-time HE. For each patient, we classified periods of benzodiazepine use by the number of days since initiation. We used Cox regression to compare the risk of HE in current benzodiazepine users vs. non-users adjusting for confounders. Results Cirrhosis patients were not at increased risk of HE for the first two days of benzodiazepine use, but then faced a five-fold increased risk of HE during days 3 to 10 of benzodiazepine use. The risk of HE was not increased for those who had been using benzodiazepines for more than 28 days. Conclusion Cirrhosis patients who had begun using benzodiazepines between 3 and 10 days previously had a markedly increased risk of developing first-time HE. Cirrhosis patients who had been using benzodiazepines for just one or two days or continued use for more than 28 days did not have such an excess risk.
APA, Harvard, Vancouver, ISO, and other styles
8

Lutz, Eric William, and Christopher Hines. "Recurrent clonazepam withdrawal delirium in a postoperative neurosurgical patient: a case report." BMJ Case Reports 14, no. 6 (June 2021): e240804. http://dx.doi.org/10.1136/bcr-2020-240804.

Full text
Abstract:
We present a case of benzodiazepine withdrawal delirium in a middle-aged man undergoing spinal surgery. Benzodiazepines were stopped prior to surgery and on postoperative day 4, the patient exhibited significant paranoia, hyperarousal and ideas of reference. Patient’s symptoms resolved after reintroduction of his benzodiazepines. It is important to include benzodiazepine withdrawal in the differential diagnosis for acute delirium even in those patients taking low or moderate doses. Benzodiazepine withdrawal delirium typically responds rapidly to restarting benzodiazepines. In patients with known discontinuation issues, early consultation with consult-liaison psychiatry and preoperative planning for early medication re-initiation is paramount.
APA, Harvard, Vancouver, ISO, and other styles
9

Summers, J., and K. W. Brown. "Benzodiazepine prescribing in a psychiatric hospital." Psychiatric Bulletin 22, no. 8 (August 1998): 480–83. http://dx.doi.org/10.1192/pb.22.8.480.

Full text
Abstract:
Using a case note study, this paper presents a longitudinal survey of the effect of psychiatric inpatient care on benzodiazepine prescribing. Standards were proposed to assess the quality of this prescribing. Based on these standards, the study shows inappropriate use of benzodiazepines. Following admission, there was an increase in the number of patients prescribed benzodiazepines and in the number of benzodiazepines prescribed. Of the benzodiazepines withdrawn, most were contrary to the proposed standard. The quality of drug history showed little emphasis being placed on rationalising benzodiazepine prescribing. The issue of how benzodiazepines should be handled during psychiatric admission is discussed.
APA, Harvard, Vancouver, ISO, and other styles
10

Cooper, Michael, Marc Safran, and Mark Eberhardt. "Caffeine Consumption among Adults on Benzodiazepine Therapy: United States 1988–1994." Psychological Reports 95, no. 1 (August 2004): 183–91. http://dx.doi.org/10.2466/pr0.95.1.183-191.

Full text
Abstract:
The concomitant use of benzodiazepines and caffeine was studied to learn if caffeine consumption varied as a function of benzodiazepine use. Caffeine may antagonize the effects of benzodiazepine and even relatively small amounts can aggravate symptoms associated with anxiety disorders. In addition, caffeine can cause or aggravate insomnia, one of the main reasons cited for use by the subjects in this analysis. Given this, there would seem to be sufficient reason for at least some users of benzodiazepines to consider, with their physicians, avoiding or limiting caffeine consumption. Data from the Third National Health and Nutrition Examination Survey were analyzed to obtain a nationally representative sample of benzodiazepine users. Subjects included 253 individuals (64% women) whose median age was 54 yr. Approximately 88% of benzodiazepine users reported caffeine consumption in the 24-hr. Dietary Recall. 26% of benzodiazepine users and 23% of nonusers reported consuming greater than 250 mg of caffeine during the 24-hr. reference period. In regression analyses, no significant relationships were found between reported caffeine consumption and benzodiazepine use. This study suggests that users and nonusers of benzodiazepines ingest similar amounts of caffeine even though some users should probably avoid or limit caffeine use.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Benzodiazepine"

1

Rizzo, Michael L. "The Prescribing Knowledge, Attitudes, and Practices among Nurse Practitioners in Maine towards Benzodiazepines." Fogler Library, University of Maine, 2004. http://www.library.umaine.edu/theses/pdf/RizzoML2004.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kavvadias, Dominique. "Liganden des Benzodiazepin-Rezeptors Studien über Benzodiazepine in pflanzlichen Geweben sowie über Hispidulin /." [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=969716087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fluck, Emma Jane. "Benzodiazepine modulation of human memory." Thesis, King's College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Elliot, Elizabeth. "Benzodiazepine tolerance and withdrawal quantified using radiotelemetry /." Title page, abstract and contents only, 1998. http://web4.library.adelaide.edu.au/theses/09PH/09phe461.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Diorio, Diane Lynn. "Peripheral benzodiazepine binding sites in psychiatric disorders." Thesis, McGill University, 1989. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=55676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bilbe, Graeme. "Molecular studies on the gaba-benzodiazepine receptor." Thesis, Imperial College London, 1985. http://hdl.handle.net/10044/1/37639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

SEROR, PAULE-MICHELE. "Les antagonistes des benzodiazepines." Lyon 1, 1989. http://www.theses.fr/1989LYO1M257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Guenoux, Charles-Albert. "Benzodiazepines : aspects pharmacologiques actuels." Aix-Marseille 2, 1990. http://www.theses.fr/1990AIX20952.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

NICOLAI, LAURENT. "Effets amnesiants des benzodiazepines." Strasbourg 1, 1992. http://www.theses.fr/1992STR15003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

MALOGNE, HERVE. "La toxicite hepatique des benzodiazepines." Amiens, 1993. http://www.theses.fr/1993AMIEM013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Benzodiazepine"

1

Cosmo, Hallström, ed. Benzodiazepine dependence. Oxford [England]: Oxford University Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hippius, H., R. R. Engel, and G. Laakmann, eds. Benzodiazepine. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lacey, Ron. That's life! survey on tranquillisers. London: British Broadcasting Corporation in association with MIND, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

F, Squires Richard, ed. GABA and benzodiazepine receptors. Boca Raton, Fla: CRC Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1944-, Hindmarch I., ed. Benzodiazepines: Current concepts : biological, clinical, and social perspectives. Chichester [England]: Wiley, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Network, Drug Abuse Warning, National Institute on Drug Abuse. Division of Epidemiology and Statistical Analysis., and CSR Incorporated, eds. A Decade of DAWN: Benzodiazepine-related cases, 1976-1985 : topical data from the Drug Abuse Warning Network. Rockville, Md. (5600 Fishers Lane, Rockville 20857): U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, Division of Epidemiology and Statistical Analysis, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cormack, Margaret A., Michael E. Dewey, and R. Glynn Owens. Reducing Benzodiazepine Consumption. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3672-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

E, Giesen-Crouse, ed. Peripheral benzodiazepine receptors. London: Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Martin, Sarter, Nutt David J. 1951-, and Lister Richard G, eds. Benzodiazepine receptor inverse agonists. New York: Wiley-Liss, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Benzo junkie: More than a case history. Ringwood, Vic., Australia: Viking, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Benzodiazepine"

1

Müller, W. E. "Die Wirkung der Benzodiazepine auf neuronaler Ebene." In Benzodiazepine, 1–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rüther, E. "Benzodiazepine zur Behandlung von Schlafstörungen." In Benzodiazepine, 101–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Martinius, J. "Benzodiazepine als Sedativa und Antikonvulsiva in der Kinder— und Jugendpsychiatrie." In Benzodiazepine, 111–13. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nissen, G. "Benzodiazepine in der Behandlung von Angstsyndromen in der Kinder— und Jugendpsychiatrie." In Benzodiazepine, 114–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Berzewski, H. "Risiken und Komplikation bei der Behandlung des alten Menschen mit Benzodiazepinen." In Benzodiazepine, 121–30. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kanowski, S. "Benzodiazepine in der Gerontopsychiatrie." In Benzodiazepine, 131–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Laakmann, G., D. Blaschke, H. Hippius, and D. Messerer. "Wirksamkeits— und Verträglichkeitsvergleich von Alprazolam gegen Amitriptylin bei der Behandlung von depressiven Patienten in der Praxis des niedergelassenen Allgemein— und Nervenarztes." In Benzodiazepine, 139–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pöldinger, W. "Die Bedeutung der Benzodiazepinderivate in der Depressionsbehandlung." In Benzodiazepine, 148–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Heimann, H. "Zukunftsperspektiven." In Benzodiazepine, 154–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gerken, A., F. Holsboer, and O. Benkert. "Untersuchung über den Einfluß von Nordiazepam auf die Plasmakonzentration von Amitriptylin und Nortriptylin." In Benzodiazepine, 158–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70621-9_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Benzodiazepine"

1

Роман Анатольевич, Калёкин,, Волкова, Алла Андреевна, Павлова, Альбина Захаровна, Орлова, Алевтина Михайловна, and Павлов, Андрей Леонидович. "TOXIC EFFECTS OF BENZODIAZEPINE RECEPTOR AGONISTS." In Теоретические основы и практическое применение инновационных исследований: сборник статей международной научной конференции (Москва, Ноябрь 2022). Crossref, 2022. http://dx.doi.org/10.37539/221111.2022.42.92.006.

Full text
Abstract:
Рассмотрена группа психотропных лекарственных средств - анксиолитиков при использовании в современной медицине с возможностью токсического воздействия на организм человека и вероятностью отравления ими. Описаны лекарственные препараты из агонистов бензодиазепиновых рецепторов применяемых в России как объекты химико-токсикологического и судебно-химического исследования. A group of psychotropic drugs - anxiolytics when used in modern medicine with the possibility of toxic effects on the human body and the likelihood of poisoning by them is considered. Medicinal preparations from benzodiazepine receptor agonists used in Russia as objects of chemical-toxicological and forensic chemical research are described.
APA, Harvard, Vancouver, ISO, and other styles
2

Deng, Fusheng, Jingling Shen, and Xianfeng Wang. "Terahertz spectroscopic study of benzodiazepine sedative hypnotics." In International Symposium on Photoelectronic Detection and Imaging 2011. SPIE, 2011. http://dx.doi.org/10.1117/12.900786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fogliano, Chiara, Bice Avallone, Chiara Maria Motta, and Rosa Carotenuto. "Influence of Benzodiazepine Delorazepam on Xenopus laevis Embryogenesis." In The 7th World Congress on Civil, Structural, and Environmental Engineering. Avestia Publishing, 2022. http://dx.doi.org/10.11159/iceptp22.194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Henry, Mark, Danny J. Eckert, Matthias Eikermann, Atul Malhotra, and Nancy L. Chamberlin. "Effects Of The Non-Benzodiazepine Sedative Eszopiclone Vs. The Benzodiazepine Temazepam On Genioglossus Muscle Activity And Ventilatory Responses To CO2 In Rats." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Michail, Emmanouil, Ioanna Chouvarda, and Nicos Maglaveras. "Benzodiazepine administration effect on EEG Fractal Dimension: results and causalities." In 2010 32nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2010). IEEE, 2010. http://dx.doi.org/10.1109/iembs.2010.5627851.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Алла Андреевна, Волкова,, Калёкин, Роман Анатольевич, Орлова, Алевтина Михайловна, Павлова, Альбина Захаровна, and Павлов, Андрей Леонидович. "HIGH-TECH TECHNIQUES FOR DETECTING BENZODIAZEPINE RECEPTOR AGONISTS IN POISONING." In Высокие технологии и инновации в науке: сборник статей международной научной конференции (Санкт-Петербург, Ноябрь 2022). Crossref, 2022. http://dx.doi.org/10.37539/221116.2022.22.27.007.

Full text
Abstract:
Рассмотрена группа психотропных лекарственных средств - анксиолитиков при использовании в современной медицине с возможностью токсического воздействия на организм человека и вероятностью отравления ими. Описаны лекарственные препараты из агонистов бензодиазепиновых рецепторов применяемых в России как объекты химико-токсикологического и судебно-химического исследования. A group of psychotropic drugs - anxiolytics when used in modern medicine with the possibility of toxic effects on the human body and the likelihood of poisoning by them is considered. Medicinal preparations from benzodiazepine receptor agonists used in Russia as objects of chemical-toxicological and forensic chemical research are described.
APA, Harvard, Vancouver, ISO, and other styles
7

Liao, K. M., L. Y. Chen, and C. Y. Chen. "Drug Safety of Benzodiazepine in Patients with Chronic Obstructive Pulmonary Disease." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dragnich, A. G., E. Locke, S. Thielke, T. Parikh, C. Battaglia, J. D. Edelman, E. R. Swenson, and V. S. Fan. "Title: Risk of COPD Exacerbations with Opioid, Benzodiazepine, and Sleep Medication Use." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6265.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Miller, Michael L., Manami Shizuka, Nathan Fishkin, Emily Reid, Katie Archer, Erin Maloney, Chen Bai, et al. "Abstract 652: Antibody-drug conjugates (ADCs) of indolino-benzodiazepine DNA-alkylating agents." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-652.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Abirou, S., A. El Assyry, B. Benali, Z. Lazar, A. Boucetta, M. Massoui, B. Lakhrissi, C. Jarmoumi, and D. Mondieig. "Theoretical study by gaussian of some molecular properties of the benzodiazepine derivatives." In 2007 ICTON Mediterranean Winter Conference. IEEE, 2007. http://dx.doi.org/10.1109/ictonmw.2007.4446969.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Benzodiazepine"

1

Marczynski, Thaddeus J. Attention Span, Anxiety and Benzodiazepine Receptors. Fort Belvoir, VA: Defense Technical Information Center, February 1991. http://dx.doi.org/10.21236/ada234549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Papadopoulos, Vassilios. Peripheral Benzodiazepine Receptor in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2002. http://dx.doi.org/10.21236/ada405505.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Papadopoulas, Vassilios. Peripheral Benzodiazepine Receptor (PBR) in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2003. http://dx.doi.org/10.21236/ada420939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Campbell, Tonya, Siyu Men, Gurnoor Brar, Samantha Singh, Mina Tadrous, Tony Antoniou, and Tara Gomes. Characterizing Prescription Benzodiazepine Use among Community-Dwelling Residents of Ontario, Canada. ODPRN, April 2021. http://dx.doi.org/10.31027/odprn.2021.01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Das, Salil K. Is Peripheral Benzodiazepine Receptor (PBR) Gene Expression Involved in Breast Cancer Suppression by Dietary Soybean Protein. Fort Belvoir, VA: Defense Technical Information Center, May 2005. http://dx.doi.org/10.21236/ada436892.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Das, Salil. Is Peripheral Benzodiazepine Receptor (PBR) Gene Expression Involved in Breast Cancer Suppression by Dietary Soybean Protein? Fort Belvoir, VA: Defense Technical Information Center, June 2006. http://dx.doi.org/10.21236/ada457465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Viswanathan, Meera, Jennifer Cook Middleton, Alison Stuebe, Nancy Berkman, Alison N. Goulding, Skyler McLaurin-Jiang, Andrea B. Dotson, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacologic Interventions. Agency for Healthcare Research and Quality (AHRQ), April 2021. http://dx.doi.org/10.23970/ahrqepccer236.

Full text
Abstract:
Background. Untreated maternal mental health disorders can have devastating sequelae for the mother and child. For women who are currently or planning to become pregnant or are breastfeeding, a critical question is whether the benefits of treating psychiatric illness with pharmacologic interventions outweigh the harms for mother and child. Methods. We conducted a systematic review to assess the benefits and harms of pharmacologic interventions compared with placebo, no treatment, or other pharmacologic interventions for pregnant and postpartum women with mental health disorders. We searched four databases and other sources for evidence available from inception through June 5, 2020 and surveilled the literature through March 2, 2021; dually screened the results; and analyzed eligible studies. We included studies of pregnant, postpartum, or reproductive-age women with a new or preexisting diagnosis of a mental health disorder treated with pharmacotherapy; we excluded psychotherapy. Eligible comparators included women with the disorder but no pharmacotherapy or women who discontinued the pharmacotherapy before pregnancy. Results. A total of 164 studies (168 articles) met eligibility criteria. Brexanolone for depression onset in the third trimester or in the postpartum period probably improves depressive symptoms at 30 days (least square mean difference in the Hamilton Rating Scale for Depression, -2.6; p=0.02; N=209) when compared with placebo. Sertraline for postpartum depression may improve response (calculated relative risk [RR], 2.24; 95% confidence interval [CI], 0.95 to 5.24; N=36), remission (calculated RR, 2.51; 95% CI, 0.94 to 6.70; N=36), and depressive symptoms (p-values ranging from 0.01 to 0.05) when compared with placebo. Discontinuing use of mood stabilizers during pregnancy may increase recurrence (adjusted hazard ratio [AHR], 2.2; 95% CI, 1.2 to 4.2; N=89) and reduce time to recurrence of mood disorders (2 vs. 28 weeks, AHR, 12.1; 95% CI, 1.6 to 91; N=26) for bipolar disorder when compared with continued use. Brexanolone for depression onset in the third trimester or in the postpartum period may increase the risk of sedation or somnolence, leading to dose interruption or reduction when compared with placebo (5% vs. 0%). More than 95 percent of studies reporting on harms were observational in design and unable to fully account for confounding. These studies suggested some associations between benzodiazepine exposure before conception and ectopic pregnancy; between specific antidepressants during pregnancy and adverse maternal outcomes such as postpartum hemorrhage, preeclampsia, and spontaneous abortion, and child outcomes such as respiratory issues, low Apgar scores, persistent pulmonary hypertension of the newborn, depression in children, and autism spectrum disorder; between quetiapine or olanzapine and gestational diabetes; and between benzodiazepine and neonatal intensive care admissions. Causality cannot be inferred from these studies. We found insufficient evidence on benefits and harms from comparative effectiveness studies, with one exception: one study suggested a higher risk of overall congenital anomalies (adjusted RR [ARR], 1.85; 95% CI, 1.23 to 2.78; N=2,608) and cardiac anomalies (ARR, 2.25; 95% CI, 1.17 to 4.34; N=2,608) for lithium compared with lamotrigine during first- trimester exposure. Conclusions. Few studies have been conducted in pregnant and postpartum women on the benefits of pharmacotherapy; many studies report on harms but are of low quality. The limited evidence available is consistent with some benefit, and some studies suggested increased adverse events. However, because these studies could not rule out underlying disease severity as the cause of the association, the causal link between the exposure and adverse events is unclear. Patients and clinicians need to make an informed, collaborative decision on treatment choices.
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, and Gui-Ping Xu. Comparative efficacy of various pharmacologic treatments of alcohol withdrawal syndrome: A systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0010.

Full text
Abstract:
Review question / Objective: Lorazepam and other benzodiazepines (BZDs) are considered the first choice for treatment of Alcohol withdrawal syndrome (AWS). But they have significant addiction potential and can cause fatal respiratory depression if used in large doses. The aim of our study is to conduct a network meta-analysis to provide some data support for the clinical treatment of AWS. The patients were persons with alcohol withdrawal. The intervention being studied must be a comparison of the efficacy of the two pharmacologic treatments. The study should not be included if two pharmacologic treatments belonging to the same category were compared. All studies must include one of the following outcomes: Clinical Institute Withdrawal Assessment, revised (CIWA-Ar) score, length of hospital stay, length of intensive care unit (ICU) stay, and the incidence of delirium or seizures. Condition being studied: Side effects and safety of eleven types of agents currently used to treat alcohol withdrawal syndrome.
APA, Harvard, Vancouver, ISO, and other styles
9

Prescription opioid and benzodiazepine medications and occupational safety and health: information for employers and healthcare providers. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, May 2021. http://dx.doi.org/10.26616/nioshpub2021116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Benzodiazepines may increase length of stay and chance of delirium in intensive care. National Institute for Health Research, December 2018. http://dx.doi.org/10.3310/signal-000700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Benzodiazepine' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography